Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD3-specific antibody-induced active tolerance: from bench to bedside.

Lucienne Chatenoud1

  • 1Centre de l'Association Claude Bernard sur les Maladies Autoimmunes and Hôpital Necker Enfants Malades IRNEM, 161 Rue de Sèvres, 75015 Paris, France. chatenoud@necker.fr

Nature Reviews. Immunology
|February 4, 2003
PubMed
Summary

CD3-specific antibodies are showing promise in treating autoimmune diabetes by restoring immune tolerance to pancreatic beta-cells. This approach clears harmful T cells and promotes long-term tolerance, offering new hope for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolution of Paediatric Cow's Milk Allergy Is Associated With Low Tfh Cell Frequencies and Elevated IL-17 and IL-22 Levels.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Screening and monitoring for presymptomatic type 1 diabetes: a time for action.

Hormone research in paediatrics·2026
Same author

Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study.

Vaccine·2026
Same author

Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab.

Diabetes care·2025
Same author

Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study.

The Lancet regional health. Europe·2025
Same author

The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.

Cold Spring Harbor perspectives in medicine·2024

Area of Science:

  • Immunology
  • Endocrinology
  • Transplantation

Background:

  • CD3-specific monoclonal antibodies were initially used as non-specific immunosuppressants in transplantation.
  • These antibodies have garnered renewed interest for their ability to induce immune tolerance.

Purpose of the Study:

  • To investigate the potential of CD3-specific antibodies in treating autoimmune diabetes by restoring immune tolerance.
  • To explore the mechanisms by which these antibodies induce disease remission and long-term tolerance.

Main Methods:

  • Studies in mouse models of autoimmune diabetes.
  • Clinical trials involving short-term administration of CD3-specific antibodies in recently diagnosed diabetes patients.

Main Results:

Related Experiment Videos

  • CD3-specific antibodies induced stable disease remission in mouse models by restoring tolerance to pancreatic beta-cells.
  • Short-term administration of CD3-specific antibodies preserved beta-cell function in recently diagnosed diabetes patients.
  • Antibodies were shown to rapidly clear pathogenic T cells and promote long-term T-cell-mediated active tolerance.

Conclusions:

  • CD3-specific antibodies are effective in arresting autoimmune diabetes by eliminating pathogenic T cells and establishing immune tolerance.
  • Transforming growth factor-beta-dependent CD4+CD25+ regulatory T cells play a crucial role in the tolerance-inducing effects of CD3-specific antibodies.